Trevena (TRVN) Reports Q2 Loss of $0.28/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to Trevena (TRVN) Reports Q2 Loss of $0.28/Share

Trevena Reports Second Quarter 2015 Financial Results and Provides a Corporate Update

August 11, 2015 7:00 AM EDT

- Enrollment complete for Phase 2b trial of TRV130 in postoperative pain following soft tissue surgery; data expected in September -

- TRV027 AHF Phase 2b trial on track to report top-line data in the second quarter of 2016 -

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced financial results for the quarter ended June 30, 2015 and provided an update regarding its ongoing... More